查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1545387

速效型胰岛素的全球市场的预测:各产品，各适应症，各流通管道，各国，企业的分析

Global Rapid Acting Insulin Market Report Forecast by Product Indication Distribution Channel, Countries and Company Analysis
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

速效胰岛素市场分析

全球速效胰岛素市场规模预计将从 2023 年的 73.6 亿美元增至 2032 年的 111.7 亿美元，复合年增长率为 4.75%。该市场主要受到糖尿病成长率和人类重组胰岛素研发投资增加的推动。

推动速效胰岛素市场成长的因素

全球糖尿病盛行率不断上升

全球糖尿病盛行率的上升也是推动速效胰岛素市场快速成长的因素之一。根据国际糖尿病联盟的数据，截至 2019 年，有 4.63 亿成年人患有糖尿病，到 2045 年，这一数字可能达到 7 亿。这种增长是由于不良饮食习惯、缺乏运动、超重和肥胖以及婴儿潮世代的老化所造成的。全球第2型糖尿病的盛行率正在增加，随着患者数量的增加，对包括胰岛素在内的高效能血糖控制产品的需求也增加。此外，诊断技术的改进有助于识别病例，新兴国家对糖尿病治疗认识的提高导致糖尿病早期检测和早期治疗的进步，速效胰岛素产品的市场正在全球扩大。

胰岛素输送系统技术的进展

增强胰岛素输送系统是全球速效胰岛素需求的主要成长因素。随着速效胰岛素的广泛使用，胰岛素笔、帮浦和智慧胰岛素输送系统的发展提高了基础推注和速效胰岛素给药的简单性和精确度。 CGM 和胰岛素帮浦的组合可以实现准确的剂量和更好的血糖控制，因为 CGM 系统提供比传统血糖自我监测更多的资讯。闭环系统，或所谓的“人工胰臟”，可以根据即时血糖水平调整胰岛素剂量，在速效胰岛素方面拥有坚实的基础。这些发展将带来更好的患者治疗结果，改善患者的生活质量，并增加使用速效胰岛素製剂的趋势，从而促使市场成长。

日益关注个人化糖尿病管理

糖尿病疾病管理中的个人化医疗将增加对速效胰岛素的需求。如今，2 型糖尿病患者在製定个人化治疗方案时会考虑患者的生活方式、饮食偏好、遗传因素等。第二种胰岛素的优点是剂量和时间更灵活。新型胰岛素（超速效）也很重要，因为它们提供了更个人化的治疗选择。个人化的糖尿病治疗方法还可以促进胰岛素敏感性遗传决定因素的研究，并有助于制定个人化治疗策略。个人化趋势的不断增长也促进了RAPI产品的多样化，尤其是速效胰岛素，预计将推动市场的进一步成长。

中国速效胰岛素市场

由于糖尿病患者数量的增加以及人们糖尿病管理知识的提高，中国的速效胰岛素市场正在不断扩大。 2021年，全球将有1.41亿成年人患有糖尿病，而中国这个全球人口最多的国家也无法倖免这项负担。

速效胰岛素对于控制餐前血糖特别有用。这些胰岛素在註射后 15 分钟内开始发挥作用，有助于防止餐后血糖升高。中国当局正努力普及糖尿病治疗和胰岛素，以促进市场扩张。然而，挑战仍然存在，包括病患教育、在农村地区发展更好的医疗保健系统以及成本问题。随着中国继续致力于医疗改革和慢性病管理，速效胰岛素市场预计将成长，为现有企业和新进业者创造机会。 2024年5月，礼来公司的抗糖尿病药物三胜?获得上市许可，进入中国市场，加剧了与丹麦同行诺和诺德在西方的竞争。

本报告提供全球速效型胰岛素市场相关调查，提供成长推动因素与课题，地区和市场区隔的分析，主要企业的分析等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 成长促进因素
  • 课题
  • 机会

第5章 全球速效型胰岛素市场

第6章 市场占有率分析

  • 各产品
  • 各适应症
  • 各流通管道
  • 各国

第7章 产品

  • Lispro胰岛素
  • Aspart胰岛素
  • Glulisine胰岛素

第8章 适应症

  • 第一型糖尿病
  • 第二型糖尿病

第9章 流通管道

  • 医院药局
  • 药妆店，零售药局
  • 网路商店

第10章 国家

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 纽西兰
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东·非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企业的分析

  • Adocia
  • Biocon Limited
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals Co. Ltd.
  • Geropharm
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Wockhardt Ltd.
简介目录

Rapid Acting Insulin Market Analysis

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11. 17 billion by 2032, from US$ 7. 36 billion in 2023. The market is mainly driven by growth rate of diabetes and the rise in investment in research and development for human recombinant insulin.

Rapid Acting Insulin Industry Overview

A rapid-acting insulin is intended to imitate the body's reaction to the consumption of various foods as industrial insulin imitates natural insulin. It causes effective response 15 minutes after injection and reaches its maximum effect after about 1 hour and lasts 2 to 4 hours. This type of insulin is generally employed for administration before meals, and for the treatment of hyperglycemia. It is taken 15 minutes before eating a meal or within 30 minutes after eating a meal; this flexibility is different from human insulin. The standard rapid-acting analogue insulins are insulin lispro insulin as part and insulin glulisine. On the basis of structure, these insulins have a more rapid onset and a relatively shorter duration of action than the regular insulin.

Globally, rapid acting insulin has turned into an essential part of controlling both type 1 and type 2 diabetes. It is employed in multiple daily injections and insulin pump therapy in the developed regions as it provides better glycemic control and increased modem freedom to the patients. The fast-acting insulin availability over the past years has increased, and people from many developing countries can get them, but issues with availability and cost remain relevant in some territories. With the rising incidence of diabetes and the improved understanding and acceptance of the benefits of achieving better control of blood glucose levels and, therefore, a reduction in the incidence of microvascular complications of diabetes by using rapid-acting insulin, its use across the world is likely to increase further. Having understood the importance of insulin, research is still being conducted to determine even faster acting insulins, and better ways of administering the insulin in the management of diabetes.

Growth Drivers of the Rapid-Acting Insulin Market

Rising global diabetes prevalence:

The global occurrence of diabetes has also risen at a high rate and this is one which has made the market for rapid acting insulin to grow rapidly as well. The International Diabetes Federation indicates that as per 2019, 463 million adults suffer from diabetes, and this figure could reach 700 million by 2045. This rise is as a result of poor dieting, physical inactivity, overweight and obesity, as well as aging baby boomers. The global type 2 diabetes prevalence is increasing, and with the increase in the number of cases, there is the demand for efficient blood glucose control products, including insulin. In addition, more identification of cases through technological enhancement in diagnosing the disease and growth awareness of diabetes care in the emerging nation progress early detection and treatment of diabetes more market for rapid-acting insulin product in the world.

Technological advancements in insulin delivery systems:

Enhancements of insulin delivery systems are prospectively the major growth contributors to the global demand of rapid-acting insulin. Growth of insulin pens, pumps, and smart insulin-delivery systems has increased the usability and accuracy of basal bolus and rapid-acting insulin administration with broader use of rapid-acting insulin. CGM and insulin pump combination makes the accurate dosing and good glycemic control because CGM systems provide more information than traditional self-monitoring of blood glucose. Closed loop systems or what is also known as 'the artificial pancreas' that regulates insulin dosage with reference to real time glucose levels has a strong foundation by virtue of rapid-acting insulins. Such developments bring the better outcomes for the patients and increase patients' quality of life, their tendency to use the rapid-acting insulins and, therefore, the market growth.

Increasing focus on personalized diabetes management:

Personalized medicine in the management of diabetic diseases increases the growth in the demand for rapid-acting insulin. Today, the patients with diabetes type 2 are developing personalized programs of the disease treatment which taken into consideration the patient's lifestyle, preferences in terms of diet, and hereditary factors. The second type of insulin has the advantage of more flexibility in dosing and in timing. Also important is that new types of insulin - ultra-rapid-acting - mean even more choice for personalized treatment. Also, the personalized approach to diabetes management fuels investigations into genetic determinants of insulin sensitivity which might contribute to development of individualized treatment strategies. The increasing trend of individualization also contributes to several RAPI products, particularly various products of rapid-acting insulin, which will unlock the market's growth further.

China Rapid Acting Insulin Market

China's market for rapid-acting insulin is expanding because of the rising instances of diabetes and people's enhanced knowledge of how to manage the condition. In 2021, 141 million adults live with the disease globally and China being the most populous country in the world is not exempted from this burden.

Fast-acting insulin or rapid-acting insulin is helpful in controlling blood sugar especially before meals. These insulins begin to act within fifteen minutes of injection and act to prevent the post-prandial rise in blood glucose. The Chinese authorities have undertaken efforts to enhance the treatment of diabetes and the availability of Insulin, thus contributing to market progression. Nevertheless, difficulties persist, such as patient enlightenment, development of a better rural health system, as well as the question of cost. Since China will maintain its efforts in the healthcare reform and the management of chronic disease, the market for rapid-acting insulin is expected to grow and can create opportunities for the existing players as well as the newcomers. In May 2024, Eli Lilly entered the Chinese market securing approval to sell its diabetes drug tripeptide, ramping up a Europe and North America fight with Danish peer Novo Nordisk.

Rapid Acting Insulin Company Analysis

The Rapid Acting Insulin market is dominated by several leading companies, including Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd. These companies are at the forefront of developing and manufacturing rapid-acting insulin products, playing a vital role in meeting the world healthcare needs of individuals with diabetes.

Rapid Acting Insulin Company News

In March 2023, Sanofi in India received marketing authorization from the Central Drugs Standard Control Organization for its diabetes medication Soliqua, available in a pre-filled pen.

In November 2023, USV Pvt Ltd and Biogenomics launched INSUQUICK, India's first biosimilar Insulin part, to improve access for people with diabetes.

April 2023, Insulet Corporation's latest innovation, Omnipod GO, has received FDA clearance as an insulin delivery device for people with type 2 diabetes, specifically for those aged 18 or older who usually require daily injections of long-acting insulin.

Product - Market breakup in 3 viewpoints:

1. Lispro Insulin

2. Aspart Insulin

3. Glulisine Insulin

Indication - Market breakup in 2 viewpoints:

1. Type 1 Diabetes

2. Type 2 Diabetes

Distribution Channel - Market breakup in 3 viewpoints:

1. Hospital Pharmacies

2. Drug Stores and Retail Pharmacies

3. Online Stores

Countries - Market breakup in 25 viewpoints:

  • North America

United States

Canada

  • Europe

France

Germany

Italy

Spain

United Kingdom

Belgium

Netherland

Turkey

  • Asia Pacific

China

Japan

India

South Korea

Thailand

Malaysia

Indonesia

Australia

New Zealand

  • Latin America

Brazil

Mexico

Argentina

  • Middle East & Africa

Saudi Arabia

UAE

South Africa

All the key players have been covered from 5 Viewpoints:

  • Overview
  • Key Persons
  • Product Portfolio
  • Recent Development
  • Revenue Analysis

Key Players Analysis:

1. Adocia

2. Biocon Limited

3. Eli Lilly and Company

4. Gan & Lee Pharmaceuticals Co. Ltd.

5. Geropharm

6. MannKind Corporation

7. Merck & Co. Inc.

8. Novo Nordisk A/S

9. Sanofi S.A.

10. Wockhardt Ltd.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges
  • 4.3 Opportunities

5. Global Rapid Acting Insulin Market

6. Market Share Analysis

  • 6.1 By Product
  • 6.2 By Indication
  • 6.3 By Distribution Channel
  • 6.4 By Countries

7. Product

  • 7.1 Lispro Insulin
  • 7.2 Aspart Insulin
  • 7.3 Glulisine Insulin

8. Indication

  • 8.1 Type 1 Diabetes
  • 8.2 Type 2 Diabetes

9. Distribution Channel

  • 9.1 Hospital Pharmacies
  • 9.2 Drug Stores and Retail Pharmacies
  • 9.3 Online Stores

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherland
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Thailand
    • 10.3.7 Malaysia
    • 10.3.8 Indonesia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 South Africa
    • 10.5.2 Saudi Arabia
    • 10.5.3 UAE

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 Adocia
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Development
    • 13.1.5 Revenue Analysis
  • 13.2 Biocon Limited
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Development
    • 13.2.5 Revenue Analysis
  • 13.3 Eli Lilly and Company
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Development
    • 13.3.5 Revenue Analysis
  • 13.4 Gan & Lee Pharmaceuticals Co. Ltd.
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Development
    • 13.4.5 Revenue Analysis
  • 13.5 Geropharm
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Development
    • 13.5.5 Revenue Analysis
  • 13.6 MannKind Corporation
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Development
    • 13.6.5 Revenue Analysis
  • 13.7 Merck & Co. Inc.
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Development
    • 13.7.5 Revenue Analysis
  • 13.8 Novo Nordisk A/S
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Development
    • 13.8.5 Revenue Analysis
  • 13.9 Sanofi S.A.
    • 13.9.1 Overview
    • 13.9.2 Key Persons
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Development
    • 13.9.5 Revenue Analysis
  • 13.10 Wockhardt Ltd.
    • 13.10.1 Overview
    • 13.10.2 Key Persons
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Development
    • 13.10.5 Revenue Analysis